MELD-ATG Trial

Low-Dose Transplant Drug Preserves Beta Cells in Young People With Type 1 Diabetes, Phase 2 Trial Finds

An adaptive trial in newly diagnosed patients identified 0.5 mg/kg as the minimum effective dose with fewer adverse events than a higher dose.